Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Small Cell Lung Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 110 (planned)
- Started
- Aug 19, 2021
- Main results expected
- Dec 10, 2029
- Fully finished
- Dec 10, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
Measured over: Up to 21 days in Cycle 1 (Cycle 1 = 21 days)
Number of Participants Who Experience at Least One Adverse Event (AE)
Measured over: Up to approximately 60 months
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
Measured over: Up to approximately 60 months
Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
Measured over: Up to approximately 60 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04938817 · record last updated 2026-06-01 · checked 2026-11-09 15:47 UTC